ATP5F1A抗体;ATP5F1A Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using ATP5F1A mouse mAb against HepG2 (1), Hela (2), HCT116 (3), mouse heart (4), and rat heart (5) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using ATP5F1A mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human breast cancer tissues using ATP5F1A mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human stomach cancer tissues using ATP5F1A mouse mAb with DAB staining.    

  
  

The ATP5F1A antibody targets the alpha subunit of mitochondrial ATP synthase (Complex V), a key enzyme in oxidative phosphorylation responsible for generating cellular ATP. ATP5F1A (also known as ATP5A1) is a core component of the F1 catalytic domain, playing a central role in coupling proton translocation across the mitochondrial membrane to ATP synthesis. This subunit contains nucleotide-binding sites critical for the enzyme’s catalytic activity and structural stability.

Antibodies against ATP5F1A are widely used in research to study mitochondrial function, energy metabolism disorders, and diseases linked to ATP synthase dysfunction, such as neurodegenerative disorders, cancer, and rare mitochondrial syndromes. They enable protein detection via techniques like Western blotting, immunofluorescence, and immunohistochemistry, aiding in the assessment of ATP5F1A expression levels, localization, and post-translational modifications.

Commercial ATP5F1A antibodies are typically raised in hosts like rabbits or mice, with validation across species including human, mouse, and rat. Researchers must verify antibody specificity due to potential cross-reactivity with homologous subunits. Recent studies also explore ATP5F1A’s role in apoptosis regulation and its dysregulation in metabolic diseases, highlighting its broader implications beyond bioenergetics. Reliable detection of ATP5F1A remains crucial for advancing mitochondrial biology and therapeutic targeting of energy metabolism pathways.